Saniona gets go ahead for phase IIa trial in obesity disorder
Danish biotech Saniona is ready to initiate phase II studies of its lead candidate in a rare disease that leads to obesity and type 2 diabetes. The company aims to add additional endpoints to the study.
BY LONNI LYNGE
A planned phase IIa study with an experimental drug from Saniona to treat a rare hereditary disease has won the necessary clearance to go ahead, the Danish biotech said this week.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Saniona share spikes on strong diabetes data
For abonnenter
Saniona expands partnership with Upsher-Smith subsidiary
For abonnenter
Saniona gets milestone payment from Michael J. Fox
For abonnenter
